|
WO2007095336A2
|
|
Production of hiv
|
|
MXPA06001996A
|
|
Immunogenic hiv compositions and related methods.
|
|
EP1355663A1
|
|
Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
|
|
ZA200108559B
|
|
HIV immunogenic compositions and methods.
|
|
WO0160415A1
|
|
Methods and compositions for gene delivery
|
|
US6737066B1
|
|
HIV immunogenic compositions and methods
|
|
OA11937A
|
|
HIV immunogenic compositions and methods.
|
|
AU6440999A
|
|
Composition for preventing or treating a T-cell mediated pathology
|
|
WO9963076A1
|
|
Novel method of large scale plasmid purification
|
|
WO9929848A1
|
|
Novel vectors and genes exhibiting increased expression
|
|
WO0011476A1
|
|
Methods for evaluating immune function
|
|
AU7101798A
|
|
Non-infectious, protease defective hiv particles and nucleic acid molecules encoding therefor
|
|
AU5528198A
|
|
Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
|
|
US5891432A
|
|
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
CA2248538A1
|
|
Targeted delivery of genes encoding interferon
|
|
AU6091296A
|
|
Method for increasing HDL cholesterol level
|
|
US5843770A
|
|
Antisense constructs directed against viral post-transcriptional regulatory sequences
|
|
US5744326A
|
|
Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
|
|
US5994316A
|
|
Method of preparing polynucleotide-carrier complexes for delivery to cells
|
|
WO9615653A2
|
|
Vial retainer
|
